Escolar Documentos
Profissional Documentos
Cultura Documentos
Aim: Most of the high-performance liquid chromatography (HPLC) methods that have been developed to measure
warfarin levels use the preextraction spiked internal standard method. We developed a new liquid-liquid extraction
(LLE) and reversed-phase HPLC method that uses a postextraction spiked internal standard for the determination of
plasma warfarin.
Materials and methods: The effect of varying the 1) mobile phase pH, 2) type and composition of organic solvents, 3)
type and concentration of buffer solutions, 4) column temperatures, 5) flow rates, 6) organic modifier, and 7) ultraviolet
wavelengths were tested.
Results: Optimum separation was achieved by using 30:70 (v/v) acetonitrile and potassium dihydrogen orthophosphate
(0.01 M) at pH 6.5 without the addition of an organic modifier at 300 nm. The column temperature was fixed at 30 C
and the flow rate at 1.0 mL/min. Phenylbutazone was the most suitable internal standard. For LLE, the optimum plasma
pH was 4.5, using 2 volumes of 2.5 mL of diethyl ether. The average retention times of warfarin and phenylbutazone
were 7 and 11 min, respectively.
Conclusion: The postextraction spiked internal standard method saved a significant amount of development time and
gave an excellent recovery of nearly 90%. This method was successfully tested using spiked human plasma. On the
whole, the developed method is simple, economical, and suitable for routine application.
Key words: Method development, HPLC, warfarin, postextraction
Introduction
Warfarin is one of the most commonly administered
oral anticoagulants used in the prophylactic treatment
of various thromboembolic disorders. Due to its wide
interindividual variability and narrow therapeutic
index, optimal determination of its dose is difficult
to achieve and suboptimal dosings remain the norm
(1). Because different ethnic groups may show
different responses to warfarin (2), many researchers
throughout the world have developed their own
detection methods for warfarin pharmacokinetic
studies for their local populations.
Some
researchers
have
utilised
gas
chromatography-mass spectrometry (GC-MS) to
quantitate warfarin levels in both biological samples
and pharmaceutical products (3-5). However, these
methods require prior derivatisation steps, which are
tedious. The heating process for sample volatilisation
may also contribute to some sample loss.
Other reports include the use of high-performance
liquid chromatography (HPLC) analyses coupled
with ultraviolet (UV) (6-8) and fluorescence (9)
detectors. Another group of researchers achieved
an exceptionally low limit of detection (0.3 ng/mL)
930
Preparation of samples
For this purpose, 3 flow rates of 0.5, 0.75, and 1.0 mL/
min were investigated and warfarins peak area and
retention times were then compared to determine
the flow rate that yielded the largest peak area or the
shortest retention time.
AU
0.5
Peak area:
(a) 13 536 856
(b) 16 796 700
(c) Not detected
(d) Not detected
1
18.934
0.6
(a)
21.278
0.7
(b)
0.4
0.3
3.514
0.2
0.1
0.0
2.0
4.0
6.0
8.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0 28.0 30.0
Min
Figure 1. Superimposed warfarin peaks when the pH of the KH2PO4 buffer was adjusted
to (a) 7.5 and (b) 6.5. Warfarin peaks were not detected when the pH was
adjusted to 5.5 (c) and 6.5 (d).
9.247
0.7
0.6
(a)
0.4
23.414
AU
0.5
Peak area:
(a) 11 950 765
(b) 17 267 408
0.3
0.2
3.767
(b)
0.1
0.0
2.0
4.0
6.0
8.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0 28.0 30.0
Min
Figure 2. Superimposed warfarin peaks when (a) ACN and (b) MeOH were used as the
mobile phase. MeOH gave an average system pressure of 3065 psi while ACNs
was lower at 2384 psi.
1.4
Peak area:
(a) 11 8 57 987
(b) 11 950 765
5
5.329
1.2
(a )
1.0
9.247
9.2
AU
0.8
0.6
(b)
3.767
0.4
0.2
0.0
2.0
4.0
6.0
8.0
10.0
Min
12.0
14.0
16.0
18.0
20.0
Figure 3. Superimposed warfarin peaks when the composition of the mobile phase was
(a) 40:60 and (b) 30:70.
9
9.689
0.9
0.7
(b))
0.5
(a )
Peak area:
(a) 16 594 923
(b) 12 082 816
(c) 19 870 420
9.306
AU
0.6
(c)
9.210
0.8
0.4
0.3
3.808
0.2
0.1
0.0
2.0
4.0
6.0
8.0
10.0
Min
12.0
14.0
16.0
18.0
20.0
0.7
(a)
AU
0.6
(b)
0.5
Peak area:
(a) 10 178 669
(b) 12 282 059
(c) 11 713 361
11.249
9
9.546
0.8
10.809
Figure 4. Superimposed warfarin peaks when (a) CH3COOK, (b) NaH2PO4, and (c)
KH2PO4 were used as the buffer solutions.
((c))
0.4
0.3
0.2
0.1
0.0
2.0
4.0
6.0
8.0
10.0
Min
12.0
14.0
16.0
18.0
20.0
Figure 5. Superimposed warfarin peaks when the buffer concentration was adjusted to
(a) 0.01 M, (b) 0.05 M, and (c) 0.1 M.
0.5
ESR
ES
4.315
AU
0.4
0.3
SDZ
DZ
3.842
0.1
IND
ND
15.289
0.2
Peak area:
(SDZ) 6 528 96 7
(ESR) 10 310 106
(PBZ) 5 846 281
(IND)18 851 492
(DSB) Not detected
(LNC) Not detected
25.935
7.872
0.6
0.0
2.0
4.0
6.0
8.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0 28.0 30.0
Min
936
(a)
0.24
3.793
0.20
AU
Peak area:
(WAR) 11 406 626
(PBZ) 5 217 702
WAR
0.16
0.12
PBZ
0.08
14.109
0.28
9.816
0.04
0.00
0.28
4.0
6.0
(b)
8.0
10.0
Min
WAR
0.24
12.0
14.0
8.963
2.0
16.0
18.0
20.0
Peak area:
(WAR) 11 438 249
(PBZ) 5 192 922
0.16
0.12
13.913
AU
0.20
PBZ
0.08
0.04
0.00
2.0
4.0
6.0
8.0
10.0
Min
12.0
14.0
16.0
18.0
20.0
0.4
(a )
AU
0.3
99.077
6.796
6.
0.5
(c)
13.340
13
Peak area:
(a) 9 030 695
(b) 12 078 646
(c) 19 403 074
(b)
0.2
0.1
0.0
2.0
4.0
6.0
8.0
10.0
Min
12.0
14.0
16.0
18.0
20.0
Figure 8. Superimposed warfarin peaks when the flow rates were set at (a) 1.0
mL/min, (b) 0.75 mL/min, and (c) 0.5 mL/min.
Peak area:
(a) 8 415 998
(b) 2 492 582
(a)
7.435
AU
0.3
7.036
0.4
0.2
(b)
0.1
0.0
2.0
4.0
Min
6.0
8.0
10.0
Figure 9. Superimposed warfarin peaks when using the mobile phase with (a)
no acetic acid and (b) 1% acetic acid.
937
0.010
Peak area:
(WAR) 3 943
(PBZ) 436 473
PBZ
11.6
11.653
0.012
(a)
AU
0.008
0.006
0.004
7.436
7.43
0.002
WAR
0.000
2.0
4.0
6.0
8.0
10.0
12.0
14.0
0.005
AU
0.004
Peak area:
(WAR) 8 471
(PBZ) 213 097
11.669
Min
PBZ
(b)
0.003
0.001
WAR
7.493
0.002
0.000
2.0
4.0
6.0
8.0
10.0
12.0
14.0
0.0012
0.0010
11.721
Min
Peak area:
(WAR) 12 585
(PBZ) 57 460
(c)
PBZ
0.0006
WAR
7.429
AU
0.0008
0.0004
0.0002
0.0000
-0.0002
2.0
4.0
6.0
8.0
10.0
12.0
14.0
Min
0.0006
0.0005
Peak area:
(WAR)11 006
(PBZ) 8 638
WAR
77.443
0.0007
(d)
0.0003
0.0002
PBZ
0.0001
11
11.645
AU
0.0004
0.0000
-0.0001
-0.0002
2.0
4.0
6.0
8.0
10.0
12.0
14.0
Min
11.678
0.032
Peak area:
(PBZ) 1 184 610
(WAR) Not detected
0.028
0.024
(e)
PBZ
AU
0.020
0.016
0.012
0.008
0.004
0.000
2.0
4.0
6.0
Min
8.0
10.0
12.0
14.0
Figure 10. Chromatograms produced when the PDA detection spectrum range was set at a) 280 nm, b) 290 nm, c) 300 nm, d) 309.4
nm, and e) 190-800 nm. The concentrations of warfarin and phenylbutazone in this test were 500 ng/mL and 20 g/mL,
respectively.
938
100
90.36
84.65
Mean % recovery
77.58
80
73.32
60
40
20
pH
0
3
3.5
4.5
5.5
6.5
120
87.67
Mean % recovery
100
88.24
89.96
87.02
80
66.55
60
40
20
0
Diethyl ether
n-hexane :
Diethyl ether
Figure 12. Mean percentage recoveries of warfarin and their standard deviations
when the sample was extracted using different organic solvents with pH
fixed at 4.5.
FDA requirements
Resolution (R s )
3.33
>2.0
1.86
2.0
2550
>2000
0.07
0.06
Peak area:
(WAR) 1 613 399
(PBZ) 428 033
WAR
66.430
4
Parameters
AU
0.05
0.04
9.971
0.03
0.02
0.01
PBZ
0.00
2.0
4.0
6.0
8.0
10.0
12.0
14.0
Min
Acknowledgement
We would like to express our gratitude to the
Universiti Sains Malaysia Research University Grant
(grant no. 1001/PPSP/815073) for providing financial
support.
References
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
1.
2.
Xie HG, Prasad HC, Kim RB, Stein CM. Allelic variants: ethnic
distribution and functional significance. Adv Drug Delivery
Rev 2002; 54: 1257-70.
Duffield PH, Birkett DJ, Wade DN, Duffield AM. Quantitation
of plasma warfarin levels by gas chromatography chemical
ionization mass spectrometry. Biomed Mass Spectrom 1979;
6: 101-4.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
941